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Japanese encephalitis (JE), caused by a
zoonotic ﬂavivirus and transmitted by
mosquitos during twilight and at night, is
the most common vaccine-preventable
viral encephalitis in rural areas from
Eastern Pakistan to Northern Queensland
in Australia and to Japan. Among the 3
billion people at theoretical risk of infec-
tion, an estimated 220 million people live
in rice-irrigated areas where the risk may
be considerably increased [1]. The impact
of pig farming (amplifying host) on the
epidemiology of JE infections is a matter
of debate, particularly in periurban areas,
but no conclusive evidence can be drawn
from the existing literature [2]. Every year,
up to 50 000 often severe JE clinical cases
occur among the resident populations, in
contrast with 1–2 cases among tourists,
expatriates, and visiting friends or rela-
tives in endemic areas [3].
The inactivated, mouse brain–derived
wild-type Nakayama strain (JE-MB)
vaccine, shown to be protective in
endemic areas [4] but causing rare severe
drug reactions, has widely been replaced
by a new, puriﬁed, formalin-inactivated
Vero cell culture–derived (IC51, JE-VC;
attenuated SA14-14-2) strain. Erra and
colleagues provide a timely answer on
how to boost JE–vaccinated subjects in a
nonendemic population, ﬁlling a relevant
gap of knowledge in travel medicine
practice and beyond. A diligently chosen
study design clearly shows that boosting
the immune response following vaccina-
tion with 2–3 doses of the previously
used JE-MB with a single dose of the
JE-VC vaccine results in noninferior im-
munogenicity to boosting with a JE-MB
vaccine. In addition, it conﬁrms the va-
lidity of the known vaccination schedules
with JE-MB and JE-VC. The decision to
assess the immunogenicity of heterolo-
gous JE vaccines is scientiﬁcally sound. It
shows that it is essential to rule out a
potential bias that may result in favoring
one vaccine over the other.
The interaction of concomitantly
administered vaccines, including those
against other ﬂaviviruses, does not appear
to negatively inﬂuence the immune
response to JE-VC on the basis of the
researchers’ data.
A randomized controlled trial would
be preferred. The small group size and
the lack of ruling out the possibility of
natural boosting are further limitations of
the study. However, such complex studies
are hardly feasible without substantial
industry support. The study of Erra et al
[5] also shows that investigator-driven
studies are increasingly necessary to
address practical questions that the user
of medicinal products need to know, in
order to provide the best and most cost-
effective service to the client or patient.
Thus, a single dose of JE-VC will
sufﬁce to successfully boost previous
priming with 2–3 doses of JE-MB vacci-
nation. Two doses of JE-VC are not re-
quired in correctly prevaccinated travelers
if the assumed correlate of a 50% plaque
reduction neutralization test titer of ≥10
[6] is protective. The question remains
how long the assumed protective level of
antibodies will last in persons exposed to
the wild-type virus and whether it is
boosted by the respective exposure.
The true risk for travelers of suffering
from the severe consequences of JE is
under debate. The slight increase of
reported JE cases among travelers over
the past 36 years reﬂects the higher
number of tourists rather than an in-
creased risk for the individual traveler.
The JE risk for 2 destinations with the
highest risk for short-term travelers, Bali
(Indonesia) and Thailand, is estimated to
be 1 case in 1 million and 3.3 million
travelers, respectively [3]. The respective
risk estimates for Swedish (1 case per 400
000) and Finnish (1 case per 257 000)
travelers to Thailand are higher [7, 8].
Even an assumed doubling of the number
of cases will result in a low risk.
The fact that a new, apparently safe
vaccine is now available is not necessarily
a reason to boost its use in a population
that may be at very limited risk. Thus, a
careful assessment of the points in favor
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of and against JE-VC vaccination must
be established. A serious and untreatable
illness justiﬁes its use. In contrast, the
very low number of cases and the rela-
tively low risk of exposure among travel-
ers as well as the high cost speak against
vaccinating. The scarce evidence of JE in-
fections among travelers indicates that
the majority of JE cases were recorded in
subjects staying >1 month in endemic
areas. However, 35% of the patients (n =
37) with a detailed descriptive risk analy-
sis [3] had traveled for <4 weeks in an
endemic setting. Two of 5 documented
cases occurred outside the assumed
transmission period in the respective
countries [3, 7]. Despite these facts, 4
weeks’ travel duration during the trans-
mission period is the current cutoff for
JE vaccine recommendation in many
countries.
WHO SHOULD BE
VACCINATED?
Beyond any doubt, all children living in
endemic areas beneﬁt greatly from JE
vaccine [4]. For travelers, long-term expa-
triates, and visiting friends and relatives,
the answer appears to be more complex
and less straightforward. The presently
available data on the risk of contracting
JE in an endemic area are not adequate
to give evidence-based advice.
Clearly, vaccinating all travelers to Asia
is not cost-efﬁcient [9]. Still, all travelers
must be informed about this severe and
often fatal disease. Exposure risks must be
rationally assessed. Travelers sleeping at
night in an open compound near unpro-
tected water and close to pig rearing in
Bali are at a higher risk than visitors to
urban centers in Thailand. Families
spending their holidays with local families
in areas with known cases are likely to
beneﬁt from vaccination, although there
are relatively few visiting friends and rela-
tives among the reported severe cases.
Experienced travel medicine experts
will base their recommendation on the
differentiation of potential exposure (du-
ration and season of travel, risk activi-
ties) and epidemiological knowledge
(itinerary) of the literature and country
reports, mixed with personal experience,
and may be in the best position to
counsel the traveler. Mosquito bite
avoidance, although not scientiﬁcally
conﬁrmed, is a useful measure to protect
travelers against JE. Using repellents on
the skin and insecticides on bednets,
fabrics, and clothing, and staying in
accommodations with screened or air-
conditioned rooms, will also protect
from other endemic arthropod-born dis-
eases (eg, malaria, dengue, and chikun-
gunya). Finally, travelers will assess the
beneﬁts and risks for themselves and on
that basis decide whether they want to
spend a considerable amount of money
on a vaccine against a disease that is
very severe but exceedingly rare. If the
travelers are aware that the risk of dying
in a road accident is many times higher
than suffering the severe consequences
of a JE infection, they may make the in-
formed decision to buy a helmet rather
than spending money on the vaccine. If
they choose to revaccinate after a previ-
ous priming JE-MB vaccination, they
will only need a single booster dose of
JE-VC.
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